Early detection is important for the clinical outcome of prostate tumors. The 5-year survival rate for patients with mid- to late-stage prostate cancer is only 35%, while patients with early-stage prostate cancer can have a 10-year survival rate of more than 95% with timely radical treatment. Although all walks of life have been calling for early detection and treatment of urological tumors, in China, prostate tumors are still not detected early enough. The proportion of patients with advanced prostate cancer is high compared to that of European and American countries, and the proportion of patients with advanced prostate cancer accounts for more than 80%, which means that the vast majority of patients cannot be cured, while in the United States, the figure is less than 10%. Therefore, confirming the diagnosis of prostate tumor requires the collaboration of multiple parties, including urology, diagnostic radiology, ultrasound, laboratory, nuclear medicine, etc. Accurate tumor markers combined with advanced imaging technology and increased personal health awareness will give more prostate tumor patients a chance for radical cure. Data show that an annual PSA examination for middle-aged men over the age of 50 is of great value for the early detection of prostate cancer. In daily life, once elevated PSA level, naked eye hematuria or abnormal lesions are found in imaging examination, you should go to a specialized hospital for standardized diagnosis and treatment in time. The main tests are: rectal DRE, transrectal ultrasound TURS, bone scan ECT, pelvic MRI, etc. The purpose of these tests is to make a comprehensive assessment of the disease, to determine whether the disease is early or advanced, whether the tumor is confined to the prostate or has metastasized to distant organs or lymph nodes. For example, ECT bone scan can identify the presence of skeletal metastases; pelvic MRI can determine whether there is enlargement of pelvic lymph nodes, and can further observe whether there is localized invasion of the prostate to the seminal vesicle gland, rectum and bladder neck. The results of these examinations play a decisive role in the selection of the patient’s treatment plan. The pathological examination of prostate puncture biopsy tissue is currently the “gold standard” for prostate cancer diagnosis. The pathological diagnosis is made by removing or excising a portion of the tumor tissue, and after many steps of processing, the pathologist will analyze the morphology and other intrinsic characteristics of the tissue cells through a microscope to determine the final diagnosis of the tumor. And puncture is now becoming the focus of attention in urology, imaging and ultrasound departments. The mode of puncture, timing of puncture, target selection of puncture, and number of needles for puncture have all become hot topics of discussion. Currently, ultrasound-guided trans-perineal prostate puncture biopsy is increasingly used internationally. The probability of infection and bleeding is greatly reduced, no special bowel preparation is required, and the procedure can be combined with MRI and other imaging techniques to perform “precise” targeted puncture, laying a solid foundation for the next step of targeted therapy.